Cellectar Biosciences, Inc.
Overview
Cellectar Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's proprietary phospholipid drug conjugate (PDC) platform is designed to specifically target cancer cells and deliver therapeutic payloads to a wide variety of cancers. Cellectar aims to transform the landscape of cancer treatment through its innovative approach.
Therapeutic areas
API / Drug Master Files
Cellectar Biosciences, Inc. holds 1 active (1 total) FDA Type II Drug Master File — identifying it as an active-substance / API supplier. Type II DMFs are filed with the FDA to support the use of an active pharmaceutical ingredient in drug applications.
- DRUG SUBSTANCE INTERMEDIATE CLR1401Active2026-03-11
FDA compliance signals
No FDA recalls, Warning Letters, or Form 483 observations are linked to Cellectar Biosciences, Inc. in our records. PharmaTek screens the full directory against live FDA enforcement data.
Is this Cellectar Biosciences, Inc.? Get in front of buyers actively sourcing.
We route real sourcing requests from pharma buyers to vetted, verified partners — qualified leads, not just a listing. Tell us what you make and we'll be in touch about becoming a Verified Supplier Partner.
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 7 days.